Tumor-suppressive role of Smad ubiquitination regulatory factor 2 in patients with colorectal cancer

Smad ubiquitination regulatory factor 2 (Smurf2) plays various roles in cancer progression. However, the correlation between Smurf2 and clinical outcomes has not been determined in patients diagnosed with colorectal cancer and colorectal liver metastases. We analyzed 66 patients with colorectal cancer who developed liver metastases. Smurf2 expression was assessed using immunohistochemical analysis of primary and metastatic liver tumors. High Smurf2 expression in both primary and metastatic tumors was significantly associated with longer overall survival time and time to surgical failure. Multivariate analyses revealed that low Smurf2 expression in primary tumors was an independent predictor of poor prognosis. In vitro experiments using colon cancer cell lines demonstrated that short interfering RNA knockdown of Smurf2 increased cell migration and tumor sphere formation. Western blot analyses revealed that Smurf2 knockdown increased the protein expression of epithelial cell adhesion molecule (EpCAM). Thus, in summary, high Smurf2 expression in cancer cells was found to be an independent predictor of better prognosis in patients with primary colorectal cancer and consequent liver metastases. The tumor-suppressive role of Smurf2 was found to be associated with cell migration and EpCAM expression; hence, Smurf2 can be considered a positive biomarker of cancer stem cell-like properties.

Automated summary

This study reveals the importance of Smurf2 in colorectal cancer and liver metastases. High expression of Smurf2 is associated with better prognosis, while low expression is a predictor of poor prognosis. In vitro experiments demonstrate that knockdown of Smurf2 enhances cell migration and tumor sphere formation, as well as increases the expression of EpCAM. Therefore, Smurf2 can be considered as a positive biomarker of cancer stem cell-like properties.